Salarius Pharmaceuticals
Yahoo Finance • 4 days ago
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade unin... Full story
Yahoo Finance • 10 days ago
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company has pro forma cash of $14 million following... Full story
Yahoo Finance • 11 days ago
Strong Earnings and Biotech Resilience Define the Midweek Momentum
DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB: KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe... Full story
Yahoo Finance • 11 days ago
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Leap Therapeutics Inc. 194,023,246 0.9093 0.585 0.8241 +0.3866 Salarius... Full story
Yahoo Finance • last month
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq) that it has regai... Full story
Yahoo Finance • 2 months ago
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) that it h... Full story
Yahoo Finance • 3 months ago
Salarius Pharmaceuticals To Implement 1-for-15 Reverse Stock Split
(RTTNews) - Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company, Thursday announced that it will implement a 1-for-15 reverse stock split effective August 15. Trading on a split-adjusted basis will begin Augu... Full story
Yahoo Finance • 3 months ago
Salarius Pharmaceuticals announces 1-for-15 reverse stock split to regain Nasdaq compliance
* Salarius Pharmaceuticals (NASDAQ:SLRX [https://seekingalpha.com/symbol/SLRX]) will implement a 1-for-15 reverse stock split effective August 15, 2025. * The split aims to meet Nasdaq’s $1 minimum bid price requirement for continued l... Full story
Yahoo Finance • 3 months ago
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new... Full story
Yahoo Finance • 5 months ago
Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a micro-cap biotech company with a market capitalization of $1.66 million, announced Tuesday that its shareholders approved three proposals at a special meeting, according to a statement based... Full story
Yahoo Finance • 7 months ago
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that M... Full story
Yahoo Finance • 8 months ago
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer Updates exp... Full story
Yahoo Finance • 2 years ago
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months Future development activities... Full story
Yahoo Finance • 2 years ago
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to identify patients th... Full story
Yahoo Finance • 2 years ago
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new... Full story
Yahoo Finance • 3 years ago
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new... Full story
Yahoo Finance • 3 years ago
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new... Full story
Yahoo Finance • 3 years ago
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to discuss future development and potential registration pathways SP-3164 targeted protein degrader preclinical data prese... Full story
Yahoo Finance • 3 years ago
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
Decision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss Future Development and Potential Registration Pathways HOUSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Salarius... Full story
Yahoo Finance • 3 years ago
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple myeloma Preclinical findings support the Company’s planned clinical development of S... Full story
